MTOR and cancer: It is interesting to speculate this may be in part due to the alteration of over-activity in the Ras/BRAF/MEK/ERK and PI3KCA/AKT/mTOR pathways, which are commonly affected by gain-of-function mutations in various types of cancer and VAs.